Comparative Pharmacology
Head-to-head clinical analysis: OVRAL versus SIMLIYA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OVRAL versus SIMLIYA.
OVRAL vs SIMLIYA
Head-to-head clinical comparison of therapeutic indices and safety profiles.
OVRAL is a combination oral contraceptive containing ethinyl estradiol and norgestrel. It inhibits ovulation by suppressing gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus, reducing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) release from the pituitary. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.
Not available; SIMLIYA is a trademarked combination drug with no established mechanism of action.
Prevention of pregnancyTreatment of moderate acne vulgaris in females at least 15 years of age who have achieved menarche and are unresponsive to topical therapies
Not FDA-approvedNo off-label uses documented
One tablet (norgestrel 0.3 mg with ethinyl estradiol 0.03 mg) orally once daily for 21 days followed by 7 days of placebo.
Insulin glargine (SIMLIYA) is a long-acting insulin analog administered subcutaneously once daily. Typical starting dose for adults with type 2 diabetes is 0.2 units/kg or 10 units once daily, adjusted based on blood glucose targets. For type 1 diabetes, total daily dose is divided; basal insulin glargine typically constitutes 40-50% of total daily dose, given once daily.
None Documented
None Documented
Norgestrel: 24–32 hours; Ethinyl estradiol: 12–18 hours; steady-state achieved after 5–7 days
Terminal elimination half-life is approximately 12 hours; clinically, steady state is achieved within 2-3 days of regular dosing.
Ethinyl estradiol is primarily metabolized by CYP3A4, with sulfation and glucuronidation pathways. Norgestrel is hydroxylated via CYP3A4 and undergoes reduction and conjugation.
Not characterized
Renal (60% as metabolites, ~40% unchanged); biliary/fecal (40%)
Renal excretion of unchanged drug accounts for ~70% of elimination; biliary/fecal excretion accounts for ~25%, with the remainder as metabolites.
Norgestrel: 93–97% bound to SHBG; Ethinyl estradiol: 97–98% bound to albumin and SHBG
~95% bound to albumin and alpha-1-acid glycoprotein.
Norgestrel: 1.5–2.5 L/kg; Ethinyl estradiol: 2.5–4.0 L/kg; extensive tissue distribution
Vd is approximately 0.15 L/kg, indicating limited extravascular distribution.
Norgestrel: ~90%; Ethinyl estradiol: ~45–50% due to first-pass metabolism
Oral bioavailability is ~90% due to extensive absorption with minimal first-pass metabolism.
No specific dose adjustment is required for mild to moderate renal impairment. Use with caution in severe renal impairment or end-stage renal disease due to potential for hormonal accumulation and adverse effects.
No specific dose adjustment is required for renal impairment. However, increased monitoring for hypoglycemia is recommended in patients with renal impairment due to reduced insulin clearance. GFR-based dose adjustments are not established; clinical judgment based on glucose monitoring is advised.
Contraindicated in patients with acute or chronic hepatic disease or history of hepatic tumors (benign or malignant). In Child-Pugh class A (mild impairment), use with caution; in Child-Pugh class B or C (moderate to severe impairment), contraindicated.
No specific dose adjustment is required for hepatic impairment. However, patients with hepatic impairment may have reduced gluconeogenesis and prolonged insulin effect, increasing hypoglycemia risk. Dose adjustment should be based on clinical response and blood glucose monitoring.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults: one tablet orally daily for 21 days followed by 7 days of placebo.
In pediatric patients (age ≥6 years) with type 1 diabetes, insulin glargine is given subcutaneously once daily. Typically, 40-50% of total daily insulin dose is given as basal insulin glargine. Starting dose: 0.2-0.4 units/kg/day, titrated based on blood glucose levels. For type 2 diabetes in children ≥6 years, starting dose is 0.2 units/kg/day subcutaneously once daily.
Not indicated for use in postmenopausal women. No specific geriatric dosing adjustments; consider increased risk of thrombosis and cardiovascular events in older women of reproductive age.
In elderly patients, initial dosing should be conservative, e.g., 2-4 units once daily, due to increased risk of hypoglycemia. Titrate slowly based on blood glucose monitoring. Renal and hepatic impairment may be common, increasing hypoglycemia risk.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with the number of cigarettes smoked, and is particularly marked in women over 35 years of age. Women who use combination oral contraceptives should be strongly advised not to smoke.
No black box warning exists as this drug is not FDA-approved.
["Thrombotic disorders: venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction","Hepatic neoplasia: liver tumors (benign and malignant)","Cervical cancer: increased risk with long-term use","Hypertension","Gallbladder disease","Carbohydrate and lipid metabolic effects","Headache (including migraine)","Bleeding irregularities (breakthrough bleeding, spotting, amenorrhea)","Depression","Ocular lesions (e.g., retinal thrombosis)","Contact lens intolerance"]
["Not applicable as drug is not approved"]
["Known or suspected pregnancy","Current or past history of thrombophlebitis or thromboembolic disorders","Cerebrovascular or coronary artery disease","Known or suspected breast cancer or other estrogen-sensitive neoplasia","Undiagnosed abnormal genital bleeding","Cholestatic jaundice of pregnancy or jaundice with prior pill use","Hepatic adenoma or carcinoma","Major surgery with prolonged immobilization","Heavy smoking (≥15 cigarettes/day) in women over 35 years of age","Known hypertriglyceridemia","Hypersensitivity to any component"]
["Not applicable"]
Data Pending Review
Data Pending Review
Avoid grapefruit juice as it may increase estrogen levels and side effect risk. St. John's wort (herbal supplement) reduces contraceptive efficacy by inducing CYP3A4. No specific food restrictions; maintain consistent intake to minimize GI upset.
No specific food restrictions. However, liraglutide delays gastric emptying, which may affect absorption of oral medications. Take oral contraceptives or antibiotics at least 1 hour before SIMLIYA injection. Avoid high-fat meals if they exacerbate gastrointestinal side effects.
FDA Pregnancy Category X. First trimester: Known teratogen; associated with cardiovascular defects, neural tube defects, and limb reduction defects. Second trimester: Risk of fetal masculinization with progestins. Third trimester: Potential for feminization of male fetuses and virilization of female fetuses; increased risk of fetal adrenal suppression.
Insufficient human data; animal studies not available. Avoid use in pregnancy unless benefit outweighs risk.
Contraindicated during breastfeeding. M/P ratio not established. Estrogens and progestins are excreted in human milk and may reduce milk production and quality. Potential adverse effects on infant include jaundice, breast enlargement, and hormonal disruption.
No data on excretion in human milk; M/P ratio unknown. Use caution, consider alternative therapies.
Contraindicated in pregnancy; no dose adjustments applicable as use is contraindicated.
No pharmacokinetic data in pregnancy; monitor clinical response and adjust dose based on tolerability and efficacy.
Category C
Category C
Ovral (norgestrel/ethinyl estradiol) is a combined oral contraceptive with high progestin potency, increasing the risk of venous thromboembolism. Consider for patients needing reliable contraception but avoid in those with migraine with aura, history of thromboembolic disorders, or liver disease. Breakthrough bleeding is common; manage by adjusting pill schedule or switching to a higher estrogen dose. Drug interactions with cytochrome P-450 inducers (e.g., rifampin, anticonvulsants) may reduce efficacy; consider backup contraception.
SIMLIYA is a fixed-ratio co-formulation of insulin degludec (70%) and liraglutide (1.8 mg/mL) indicated for type 2 diabetes. Monitor renal function; liraglutide is not recommended with eGFR <15 mL/min/1.73m2. Avoid co-administration with DPP-4 inhibitors due to additive DPP-4 inhibition. Titrate dose based on fasting blood glucose; maximum dose is 50 dose units (50 units insulin degludec / 1.8 mg liraglutide). Do not use in patients with gastroparesis.
Take one tablet at the same time daily; missed pills require backup contraception.Common side effects include nausea, headache, and breast tenderness; these often improve after a few cycles.Report symptoms of thromboembolism (leg pain/swelling, sudden chest pain or dyspnea) or stroke (severe headache, vision changes).Do not smoke while on Ovral; smoking increases risk of serious cardiovascular side effects, especially if over 35 years old.Antibiotics (except rifampin) do not reduce efficacy; but certain anticonvulsants and St. John's wort do; use backup method with these.
Administer once daily subcutaneously at the same time each day, preferably with the largest meal.Never share your SIMLIYA pen with others, even if the needle is changed.Monitor for signs of hypoglycemia (shakiness, sweating, confusion) and treat with fast-acting sugar.Report persistent nausea, vomiting, or abdominal pain; may indicate pancreatitis.Do not use if you have a personal or family history of medullary thyroid carcinoma or MEN2.Store unopened pens in refrigerator at 36°F to 46°F; opened pens can be kept at room temperature for up to 30 days.